

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

For patients, consult your healthcare provider prior to any medication or dose changes.

This pharmacogenomics report is based on genotypes analyzed by Phenomics Health and the patient's currently available medication list to support clinical treatment decisions.

*Current medications: ARIPIRAZOLE, ATORVASTATIN, CLOPIDOGREL, ESCITALOPRAM, GLIPIZIDE, METOPROLOL, TRAMADOL

**Antidepressants
and Anxiolytics**

**Analgesics and
Other CNS Agents**

**Antipsychotics and
Anticonvulsants**

PRESCRIBE AS DIRECTED

Alprazolam (Xanax®)
Amoxapine (Asendin®)
Bupropion (Wellbutrin SR®)
Buspirone (BuSpar®)
Citalopram (Celexa®)
Clobazam (Onfi®)
Clonazepam (Klonopin®)
Desvenlafaxine (Pristiq®)
Diazepam (Valium®)
Duloxetine (Cymbalta®)
***Escitalopram (Lexapro®)**
Esketamine (Spravato®)
Eszopiclone (Lunesta®)
Ketamine (Ketalar®)
Lorazepam (Ativan®)
Fluoxetine (Prozac®)
Fluvoxamine (Luvox®)
Imipramine (Tofranil®)
Mirtazapine (Remeron®)
Oxazepam (Serax®)
Paroxetine (Paxil®)
Protriptyline (Vivactil®)
Temazepam (Restoril®)
Trazodone (Desyrel®)
Trimipramine (Surmontil®)
Zolpidem (Ambien®)

Buprenorphine (Subutex®)
Celecoxib (Celebrex®)
Clonidine (Catapres®)
Dexmethylphenidate (Focalin®)
Dextroamphetamine (Adderall®)
Diclofenac (Voltaren®)
Fentanyl (Sublimaze®)
Flurbiprofen (Ansaid®)
Guanfacine (Intuniv®)
Hydromorphone (Exalgo®)
Ibuprofen (IBU, Motrin®)
Indomethacin (Indocin SR)
Lisdexamfetamine (Vyvanse®)
Lofexidine (Lucemyra®)
Lornoxicam (Xefocam®)
Meloxicam (Mobic®)
Methadone (Dolophine®,
Methadose®)
Methylphenidate (Concerta®)
Morphine (MS Contin®)
Naloxone (Narcan®)
Naltrexone (ReVia®)
Naproxen (Naprosyn®)
Oxycodone (Roxicodone®)
Piroxicam (Feldene®)
Tenoxicam (Mobiflex®)

Carbamazepine (Eptol®,
Tegretol®)
Cariprazine (Vraylar®)
Chlorpromazine (Thorazine®)
Clozapine (Clozaril®,
FazaClo®)
Fluphenazine (Prolixin®)
Lurasidone (Latuda®)
Olanzapine (Zyprexa®)
Paliperidone (Invega®)
Phenytoin (Dilantin®)
Pimozide (Orap®)
Primidone (Mysoline®)
Quetiapine (Seroquel®)
Risperidone (Risperdal®)
Thioridazine (Mellaril®)
Topiramate (Topamax®,
Topiragen®)

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

For patients, consult your healthcare provider prior to any medication or dose changes.

This pharmacogenomics report is based on genotypes analyzed by Phenomics Health and the patient's currently available medication list to support clinical treatment decisions.

*Current medications: ARIPIPRAZOLE, ATORVASTATIN, CLOPIDOGREL, ESCITALOPRAM, GLIPIZIDE, METOPROLOL, TRAMADOL

Antidepressants
and Anxiolytics

Analgesics and
Other CNS Agents

Antipsychotics and
Anticonvulsants

MAJOR GENE-DRUG INTERACTIONS

Amitriptyline (Elavil®)	5	Donepezil (Aricept®)	4	Brexiprazole (Rexulti®)	4
Clomipramine (Anafranil®)	5	Codeine (Fioricet®)	4	Brivaracetam (Briivact®)	4
Desipramine (Norpramin®)	2,5	*Tramadol (Ultram®)	3	Fosphenytoin (Cerebyx®)	1,2,4
Vilazodone (Viibryd®)	3			Haloperidol (Haldol®)	4
				Iloperidone (Fanapt®)	2,4
				Lamotrigine (Lamictal®)	3
				Ziprasidone (Geodon®)	3

MODERATE GENE-DRUG INTERACTIONS

Doxepin (Sinequan®)	1,4	Amphetamine(Adderall®)	2,4	*Aripiprazole (Abilify®)	2,4
Nortriptyline (Pamelor®)	5	Atomoxetine (Strattera®)	2,4	Oxcarbazepine (Trileptal®)	1,2
Sertraline (Zoloft®)	4	Hydrocodone (Lorcet HD®, Lortab®, Norco®)	3	Perphenazine (Trilafon®)	2,4
Venlafaxine (Effexor XR®)	4	Galantamine	4	Valproic Acid (Depakene®)	2
Vortioxetine (Trintellix®)	4	Lithium (Eskalith®, Lithobid®)	2		

CLINICAL IMPACT

- Medication is contraindicated by the FDA for this genotype.
- Genotype may result in higher risk for adverse drug reactions.
- Genotype may result in reduced efficacy.
- Higher systemic concentrations may require lower doses.
- Lower systemic concentrations may require higher doses.
- Medication efficacy is based on clinical values other than genotype.

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

MEDICATIONS AFFECTED BY MAJOR INTERACTIONS

Medication	Genes	Recommendations	Source
Amitriptyline	CYP2C19, CYP2D6	Avoid use. If warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	CPIC
Brexiprazole	CYP2D6	Use half the standard dose.	DPWG
	DRD2	May cause significant variability in response. Avoid use.	Ref 29
Brivaracetam	CYP2C19	May have higher systemic concentrations and higher adverse reaction risk.	FDA
Clomipramine	CYP2C19, CYP2D6	Avoid use. If warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	CPIC
Codeine	CYP2D6	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	CPIC
	OPRM1	May cause a decrease in drug efficacy	Ref 58, 59, 61, 62, 63, 64
Desipramine	CYP2D6	Avoid use. If warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	CPIC
Donepezil	CYP2D6	Alters systemic concentration	FDA
Fosphenytoin	CYP2C9, HLA-B	If patient is phenytoin-naïve, do not use phenytoin/ fosphenytoin. Avoid carbamazepine and oxcarbazepine.	CPIC
Haloperidol	CYP2D6	Reduce dose by 50% or select alternative drug (e.g., flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine).	DPWG
lloperidone	CYP2D6	Greater risk for higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dose by 50%.	FDA
Lamotrigine	ABCB1	May cause a variable drug response. Consider an alternative	Ref 96
*Tramadol	CYP2D6	Avoid use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.	CPIC
Vilazodone	ABCB1	May require a lower dose due to an increase in drug exposure	Ref 97, 160, 161, 162, 163, 164
Ziprasidone	DRD2	May cause a decrease in drug efficacy	Ref 45, 47, 48, 49, 50, 51, 165, 166, 167

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

MEDICATIONS AFFECTED BY MODERATE INTERACTIONS

Medication	Genes	Recommendations	Source
Amphetamine	CYP2D6	May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.	FDA
*Aripiprazole	CYP2D6	Reduce maximum dose to 10 mg/day or 300mg/month (67% of the maximum recommended dose).	DPWG
Atomoxetine	CYP2D6	CHILD: Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider a proportional dose increase. If unacceptable side effects are present at any time, consider a reduction in dose. ADULT: Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider a proportional dose increase. If unacceptable side effects are present at any time, consider a reduction in dose.	CPIC
Doxepin	CYP2C19, CYP2D6	Avoid use. If warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	CPIC
Galantamine	CYP2D6	Results in higher systemic concentrations. Titrate dosage based on tolerability.	FDA
Hydrocodone	CYP2D6	Use label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.	CPIC
Amphetamine	DRD2	May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.	FDA
Lithium	CACNA1C	May cause an increased risk of adverse drug reaction. Avoid use	Ref 17, 22, 24, 28
Nortriptyline	CYP2D6	Avoid use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6 (e.g., escitalopram). If a nortriptyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	CPIC
Oxcarbazepine	HLA-B	If patient is oxcarbazepine naïve, do not use oxcarbazepine.	CPIC
Perphenazine	CYP2D6	Greater risk of side effects due to higher drug concentrations	FDA

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

MEDICATIONS AFFECTED BY MODERATE INTERACTIONS

Medication	Genes	Recommendations	Source
Sertraline	<i>CYP2C19</i>	Initiate therapy with recommended starting dose (25mg/d or 50mg/d, depending on age and indication).	CPIC
	<i>HTR2A</i>	May cause an increased risk of adverse drug reaction. Consider an alternative	Ref 6, 8, 9
Valproic Acid	<i>CPS1</i>	May cause an increased risk of severe adverse drug reaction. Avoid use	Ref 20
Venlafaxine	<i>CYP2D6</i>	Select alternative drug not predominantly metabolized by CYP2D6 (e.g., escitalopram) or reduce the dose and monitor patient's plasma metabolite level.	DPWG
Vortioxetine	<i>CYP2D6</i>	Greater risk of higher systemic concentrations. The maximum recommended dose is 10 mg/d.	FDA

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02
Clinician: Marcus Blutarski
Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

PATIENT GENETICS

Gene	Genotype	Phenotype
<i>ABCB1</i>		A/A, A/A, A/A Normal Function
<i>ADRA2A</i>	rs1800544	C/C Decreased Function
<i>BDNF</i>		C/C Normal Function
<i>CACNA1C</i>		G/G, G/G Normal Function
<i>COMT</i>	rs4680	A/A Decreased Function
<i>CPS1</i>		T/T Normal Function
<i>CYP1A2</i>		*1/*1 Normal Function
<i>CYP2B6</i>		*1/*1 Normal Function
<i>CYP2C9</i>		*1/*1 Normal Function
<i>CYP2C19</i>		*1/*1 Normal Function
<i>CYP2D6</i>	rs1135840, rs16947	2N *1/*2 Increased Function
<i>CYP3A4</i>		*1/*1 Normal Function
<i>CYP3A5</i>		*1/*1 Normal Function
<i>DRD2</i>		T/T Normal Function
<i>GRIK1</i>		C/C Normal Function
<i>GRIK4</i>	rs1954787	C/C Increased Function
<i>HLA-A</i>	rs1061235	*31:01 Increased Risk
<i>HLA-B</i>	rs10484555, rs144012689	*15:02 Increased Risk
<i>HTR2A</i>		C/C, G/G, C/C, C/C, G/G, G/G Normal Function
<i>HTR2C</i>		C/C, C/C Normal Function
<i>MC4R</i>		C/C Normal Function
<i>OPRM1</i>	rs1799971	G/G Decreased Function
<i>UGT1A1</i>	rs35350960	*27/*27 Decreased Function
<i>UGT2B15</i>		*1/*1 Normal Function

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02

Clinician: Marcus Blutarski

Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST

Sample Collection: Nov. 23, 2022 13:14 EST

TEST PANEL INFORMATION

The PredictScript™ diagnostic assay is based on evidence from clinical trials and scientific literature. Detailed information about references is available upon request, and from www.phenomicshealth.com/references. Results from studies of the genetic basis of drug response variation and adverse drug events have been examined in hundreds of thousands of curated patient samples and updated based on measures of scientific and clinical validity. In parallel, ongoing pharmacometabolomic analyses from the Company's proprietary PreciMed® diagnostic platform can help power improvements in accuracy and inform the validation of the PredictScript™ assay.

Primary information on single nucleotide polymorphisms (SNPs), copy number variants (CNVs), and other genome variants were referenced from clinical significance Reference SNP reports of the National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), and National Institutes of Health (NIH)⁹. These include results from the Human Genome Variation Society¹⁰, the reference genome browser of the University of California Santa Cruz¹¹, and the Clinical Genome consortium⁵.

Genotypes specified by rsID numbers are informed by the NCBI of the NIH and, where applicable, star (*) alleles as described on Phenomics Health Inc. web portal. All genotype data are translated from star allele nomenclature into rsID numbers, based on standards used in clinical genetics^{6,7}. Star alleles are also provided to increase usability; however, star allele haplotypes and diplotypes were derived based on patients of European ancestry and may not be applicable to all patients. Assignment of variants to specific genes is provided for reference only, as polymorphisms located in a specified gene may not always be indicative of the function of the gene in which it is located.

The following genetic variants are evaluated in this test: CYP1A2 (rs762551, rs2069514, rs12720461, rs35694136, rs2069526, rs72547511, rs72547513, rs11631198, rs2093434, rs2470890, rs2134688, rs3818740); CYP2B6 (rs2279343, rs3745274, rs28399499, rs11083595, rs8109525, rs2054675); CYP2C9 (rs1799853, rs1057910, rs56165452, rs28371686, rs9332131, rs7900194, rs28371685, rs9332239); CYP2C19 (rs4244285, rs4986893, rs28399504, rs56337013, rs12248560, rs77957608, rs61886222); CYP2D6 (rs28371706, rs1065852, rs1135840, rs16947, rs3892097, rs769258, rs5030862, rs201377835, rs5030867, rs765776661, rs5030656, rs35742686, rs72549353, rs5030655, rs774671100, rs1080985, rs59421388, rs28371725); CYP3A4/CYP3A5 (rs2740574, rs35599367, rs776746, rs10264272, rs17161937, rs41303343); ABCB1 (rs1128503, rs2032582, rs1045642); ADRA2A (rs1800544); BDNF (rs6265); CACNA1C (rs3819536, rs2007004); COMT (rs4680); CPS1 (rs715); DRD2 (rs1799978); GRIK1 (rs2832407); GRIK4 (rs1954787, rs12800734); HLA-A (rs1116221, rs2523979, rs1061235); HLA-B (rs10484555, rs144012689); HTR2A (rs6311, rs6305, rs9316233, rs2770296, rs6313, rs6314); HTR2C (rs3813929, rs518147); MC4R (rs489693); OPRM1 (rs1799971); UGT1A1 (rs4148323, rs35350960, rs887829); and UGT2B15 (rs1902023).

This test does not provide medical advice and is not approved by the U.S. Food & Drug Administration (FDA). Information on pharmacogene variants specified by the FDA^{1,2}, Clinical Pharmacogenetics Implementation Consortium (CPIC)³, and Dutch Pharmacogenetics Working Group (DPWG) of the European Medicines Agency⁴, including genes involved in absorption, distribution, metabolism, and excretion (ADME), are sourced from Sequence2Script¹². Further information provided by this test may be based on Phenomics Health's interpretation of scientific literature and the pharmacokinetic and pharmacodynamic properties of drugs sourced outside of Sequence2Script. The information provided in this report is believed to be current, accurate, and consistent with available scientific literature and the described research. This information may not necessarily be clinically validated for any specific patient population. The pharmacogenomic technology and report is used to support clinical decisions. The healthcare professional directly managing the patient's care is responsible for all decisions made regarding said patient's care, including prescribing decisions made with consideration for the patient's genetic information.

This test was performed by a lab with CLIA #23D2194915 and approved by the Laboratory Director Srinivas Narayan, Ph.D.

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.

James Cook

DOB: 1956-03-02

Clinician: Marcus Blutarski

Order No: SA0008124-K24

Sample Analysis: Nov. 21, 2022 09:35 EST
Sample Collection: Nov. 23, 2022 13:14 EST

PATIENT PHARMACOGENE CARD

 <h3>Patient Pharmacogenomic Gene-Drug Interaction Card</h3> <p>Jane Doe</p>	
MAJOR GENE-DRUG INTERACTIONS	
<p><u>Antidepressants and Anxiolytics</u></p> <p>Amitriptyline Clomipramine Desipramine Vilazodone</p>	<p><u>Analgesics and Other CNS Agents</u></p> <p>Donepezil Codeine Tramadol</p>
<p><u>Antipsychotics and Anticonvulsants</u></p> <p>Fosphenytoin Haloperidol Iloperidone Lamotrigine Ziprasidone</p>	<p>FOR USE BY YOUR HEALTHCARE PROFESSIONALS ONLY</p> <p>This card contains information about medications that should be avoided based on your genetics. This may help your healthcare provider make clinical decisions for your medication therapy to avoid certain gene-drug interactions.</p> <p>Do NOT stop or change your medication or dosage without discussing with your healthcare provider</p>

This test was developed and its performance characteristics determined by Phenomics Health Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes, though results should not be intended for use as a sole means for a clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research.